18F-FDG positron emission tomography for the assessment of histological response to neoadjuvant chemotherapy in osteosarcomas: A meta-analysis

Surgical Oncology

Volumn 21, Issue 4, 2012, Pages

  Li, Hongtao ^a   Zhao, Hui ^a   Wang, Bingshun ^b   Wang, Xiaojin ^b   Wang, Zhiyu ^a   Zheng, Shuier ^a   He, Aina ^a   Sun, Yuanjue ^a   Daliu, Min ^a   Shen, Zan ^a   Yao, Yang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

18F FDG positron emission tomography; Necrosis; Response evaluation

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER ADJUVANT THERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HUMAN; META ANALYSIS; OSTEOSARCOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

BONE NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; META-ANALYSIS AS TOPIC; NEOADJUVANT THERAPY; OSTEOSARCOMA; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS;

EID: 84867866576     PISSN: 09607404     EISSN: 18793320     Source Type: Journal    
DOI: 10.1016/j.suronc.2012.07.002     Document Type: Review

References (37)

1. P. Picci Osteosarcoma (osteogenic sarcoma) Orphanet Journal of Rare Diseases 2 2007 6
2. P.A. Meyers, and R. Gorlick Osteosarcoma Pediatric Clinics of North America 44 1997 973 989
3. G. Bacci, A. Longhi, M. Versari, M. Mercuri, A. Briccoli, and P. Picci Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution Cancer 106 2006 1154 1161
4. M.P. Link, A.M. Goorin, A.W. Miser, A.A. Green, C.B. Pratt, and J.B. Belasco The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity The New England Journal of Medicine 314 1986 1600 1606
5. A.M. Davis, R.S. Bell, and P.J. Goodwin Prognostic factors in osteosarcoma: a critical review Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 12 1994 423 431
6. H.M. Quarles van Ufford, H. van Tinteren, S.G. Stroobants, I.I. Riphagen, and O.S. Hoekstra Added value of baseline 18F-FDG uptake in serial 18F-FDG PET for evaluation of response of solid extracerebral tumors to systemic cytotoxic neoadjuvant treatment: a meta-analysis Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 51 2010 1507 1516
7. M. Schulte, D. Brecht-Krauss, M. Werner, E. Hartwig, M.R. Sarkar, and P. Keppler Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 40 1999 1637 1643
8. D.S. Hawkins, S.M. Schuetze, J.E. Butrynski, J.G. Rajendran, C.B. Vernon, and E.U. Conrad [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 23 2005 8828 8834
9. D.S. Hawkins, J.G. Rajendran, E.U. Conrad 3rd, J.D. Bruckner, and J.F. Eary Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography Cancer 94 2002 3277 3284
10. L.L. Gaston, C. Di Bella, J. Slavin, R.J. Hicks, and P.F. Choong 18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different Skeletal Radiology 40 2011 1007 1015
11. C. Franzius, J. Sciuk, C. Brinkschmidt, H. Jurgens, and O. Schober Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis Clinical Nuclear Medicine 25 2000 874 881
12. T. Denecke, P. Hundsdorfer, D. Misch, I.G. Steffen, S. Schonberger, and C. Furth Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters European Journal of Nuclear Medicine and Molecular Imaging 37 2010 1842 1853
13. C.M. Costelloe, H.A. Macapinlac, J.E. Madewell, N.E. Fitzgerald, O.R. Mawlawi, and E.M. Rohren 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 50 2009 340 347
14. N. Nair, A. Ali, A.A. Green, G. Lamonica, H. Alibazoglu, and B. Alibazoglu Response of osteosarcoma to chemotherapy. Evaluation with F-18 FDG-PET Scans Clinical Positron Imaging: Official Journal of the Institute for Clinical P.E.T 3 2000 79 83
15. Z. Ye, J. Zhu, M. Tian, H. Zhang, H. Zhan, and C. Zhao Response of osteogenic sarcoma to neoadjuvant therapy: evaluated by 18F-FDG-PET Annals of Nuclear Medicine 22 2008 475 480
16. A. Iagaru, R. Masamed, S.P. Chawla, L.R. Menendez, A. Fedenko, and P.S. Conti F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas Clinical Nuclear Medicine 33 2008 8 13
17. T.L. Huang, R.S. Liu, T.H. Chen, W.Y. Chen, H.C. Hsu, and Y.C. Hsu Comparison between F-18-FDG positron emission tomography and histology for the assessment of tumor necrosis rates in primary osteosarcoma Journal of the Chinese Medical Association: JCMA 69 2006 372 376
18. M. Salzer-Kuntschik, G. Delling, G. Beron, and R. Sigmund Morphological grades of regression in osteosarcoma after polychemotherapy - study COSS 80 Journal of Cancer Research and Clinical Oncology 106 Suppl. 1983 21 24
19. P. Whiting, A.W. Rutjes, J.B. Reitsma, P.M. Bossuyt, and J. Kleijnen The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews BMC Medical Research Methodology 3 2003 25
20. H. Young, R. Baum, U. Cremerius, K. Herholz, O. Hoekstra, and A.A. Lammertsma Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group European Journal of Cancer 35 1999 1773 1782
21. J.N. Tewfik, and G.S. Greene Fluorine-18-deoxyglucose-positron emission tomography imaging with magnetic resonance and computed tomographic correlation in the evaluation of bone and soft-tissue sarcomas: a pictorial essay Current Problems in Diagnostic Radiology 37 2008 178 188
22. R.E. Reiman PET tracers for osteosarcoma Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 45 2004 1424 author reply 1424-5
23. C. Nanni, M.C. Marzola, D. Rubello, and S. Fanti Positron emission tomography for the evaluation of soft-tissue sarcomas and bone sarcomas European Journal of Nuclear Medicine and Molecular Imaging 36 2009 1940 1943
24. W. Brenner, K.H. Bohuslavizki, and J.F. Eary PET imaging of osteosarcoma. Journal of nuclear medicine: official publication Society of Nuclear Medicine 44 2003 930 942
25. A.L. Folpe, R.H. Lyles, J.T. Sprouse, E.U. Conrad 3rd, and J.F. Eary (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 6 2000 1279 1287
26. M. Charest, M. Hickeson, R. Lisbona, J.A. Novales-Diaz, V. Derbekyan, and R.E. Turcotte FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases European Journal of Nuclear Medicine and Molecular Imaging 36 2009 1944 1951
27. M.S. Kim, S.Y. Lee, W.H. Cho, W.S. Song, J.S. Koh, and J.A. Lee Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients Annals of Surgical Oncology 15 2008 906 914
28. C.M. Costelloe, A.K. Raymond, N.E. Fitzgerald, O.R. Mawlawi, R.F. Nunez, and J.E. Madewell Tumor necrosis in osteosarcoma: inclusion of the point of greatest metabolic activity from F-18 FDG PET/CT in the histopathologic analysis Skeletal Radiology 39 2010 131 140
29. T. Volker, T. Denecke, I. Steffen, D. Misch, S. Schonberger, and M. Plotkin Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 25 2007 5435 5441
30. J. Sato, T. Yanagawa, Y. Dobashi, T. Yamaji, K. Takagishi, and H. Watanabe Prognostic significance of 18F-FDG uptake in primary osteosarcoma after but not before chemotherapy: a possible association with autocrine motility factor/phosphoglucose isomerase expression Clinical Experimental Metastasis 25 2008 427 435
31. M.R. Benz, V. Evilevitch, M.S. Allen-Auerbach, F.C. Eilber, M.E. Phelps, and J. Czernin Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 49 2008 1038 1046
32. D.N. Jones, G.B. McCowage, H.D. Sostman, D.M. Brizel, L. Layfield, and H.C. Charles Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 37 1996 1438 1444
33. C. Franzius, S. Bielack, S. Flege, J. Sciuk, H. Jurgens, and O. Schober Prognostic significance of (18)F-FDG and (99m)Tc-methylene diphosphonate uptake in primary osteosarcoma. Journal of nuclear medicine: official publication Society of Nuclear Medicine 43 2002 1012 1017
34. K. Hamada, Y. Tomita, A. Inoue, T. Fujimoto, N. Hashimoto, and A. Myoui Evaluation of chemotherapy response in osteosarcoma with FDG-PET Annals of Nuclear Medicine 23 2009 89 95
35. G.J. Cheon, M.S. Kim, J.A. Lee, S.Y. Lee, W.H. Cho, and W.S. Song Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI. Journal of nuclear medicine: official publication Society of Nuclear Medicine 50 2009 1435 1440
36. J. Bajpai, R. Kumar, V. Sreenivas, M.C. Sharma, S.A. Khan, and S. Rastogi Prediction of chemotherapy response by PET-CT in osteosarcoma: correlation with histologic necrosis Journal of Pediatric Hematology Oncology 33 2011 e271 e278
37. J.J. Deeks Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests BMJ 323 2001 157 162